ChemicalBook > CAS DataBase List > SU 6668
SU 6668
- Product Name
- SU 6668
- CAS No.
- 210644-62-5
- Chemical Name
- SU 6668
- Synonyms
- SU 6668;(Z)-SU6668;(Z)-TSU-68;(Z)-Orantinib;(Z)-Orantinib/SU6668/TSU-68);PDGFR Tyrosine Kinase Inhibitor VI, SU6668;PDGFR Tyrosine Kinase Inhibitor VI, SU6668 - CAS 210644-62-5 - Calbiochem;3-[2,4-dimethyl-5-[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoicacid;3-(2,4-Dimethyl-5-{[(3Z)-2-oxo-1H-indol-3-ylidene]methyl}-1H-pyrrol-3-yl)propanoic acid;3-(2,4-Dimethyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrol-3-yl)-propionic acid
- CBNumber
- CB91312244
- Molecular Formula
- C18H18N2O3
- Formula Weight
- 310.35
- MOL File
- 210644-62-5.mol
More
Less
SU 6668 Property
- storage temp.
- +2C to +8C
- solubility
- DMSO : 50 mg/mL (161.11 mM; Need ultrasonic)
- form
- Dark yellow solid
- color
- Orange to red
More
Less
N-Bromosuccinimide Price
Sigma-Aldrich
- Product number
- CDS023028
- Product name
- 2,4-Dimethyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-pyrrole-3-propanoic acid
- Packaging
- 100MG
- Price
- $308
- Updated
- 2023/01/07
Tocris
- Product number
- 3335
- Product name
- SU6668
- Purity
- ≥99%(HPLC)
- Packaging
- 10
- Price
- $208
- Updated
- 2021/12/16
TRC
- Product number
- D457088
- Product name
- (Z)-3-(2,4-Dimethyl-5-((2-oxoindolin-3-ylidene)methyl)-1H-pyrrol-3-yl)propanoicacid(SU-6668)
- Packaging
- 5mg
- Price
- $90
- Updated
- 2021/12/16
Usbiological
- Product number
- 256776
- Product name
- SU 6668
- Packaging
- 10mg
- Price
- $466
- Updated
- 2021/12/16
Matrix Scientific
- Product number
- 132613
- Product name
- (Z)-3-(2,4-Dimethyl-5-((2-oxoindolin-3-ylidene)-methyl)-1H-pyrrol-3-yl)propanoicacid
- Purity
- 97%
- Packaging
- 250mg
- Price
- $537
- Updated
- 2021/12/16
More
Less
SU 6668 Chemical Properties,Usage,Production
Uses
PDGFR Tyrosine Kinase Inhibitor VI, SU6668 is a potent ATP-competitive inhibitor against tyrosine kinases.
General Description
A cell-permeable indolinone compound that acts as a potent ATP-competitive inhibitor against RTKs (receptor tyrosine kinases) Kit, PDGFRβ, VEGFR2 (Flk-1/KDR), FGFR1 activity in vitro (IC50 = 0.01, 0.1, 3.9, and 3.8 μM, respectively) and PDGF/VEGF/bFGF-mediated angiogenesis and tumor development in vivo. Although initially characterized as an RTK inhibitor, SU6668 is now also known to target ser/thr kinases Aurora A, Aurora B, TBK1 (NAK/T2K), and AMPK (IC50 = 0.85, 0.047, 1.4, and 1.8 μM, respectively), as well as non-receptor TKs Lyn and Yes (IC50 = 4.3 and 5.8 μM, respectively).
SU 6668 Preparation Products And Raw materials
Raw materials
Preparation Products
More
Less
SU 6668 Suppliers
- Tel
- Fax
- 86-21-57758967
- sales@boylechem.com
- Country
- China
- ProdList
- 2922
- Advantage
- 55
- Tel
- 025-83697070
- Fax
- +86-25-83453306
- info@chemlin.com.cn
- Country
- China
- ProdList
- 19172
- Advantage
- 64
- Tel
- 025-58196018 800028039
- Fax
- 025-83453306
- sales@fartop.net
- Country
- China
- ProdList
- 2229
- Advantage
- 55
- Tel
- 021-61415566 800-8193336
- orderCN@merckgroup.com
- Country
- China
- ProdList
- 51456
- Advantage
- 80
- Tel
- Fax
- -
- eric_feng1954@126.com
- Country
- China
- ProdList
- 9248
- Advantage
- 55
- Tel
- 13951936332 18305166317
- Fax
- -
- info@serpharm.com
- Country
- China
- ProdList
- 493
- Advantage
- 55
- Tel
- 571-89925085
- Fax
- 0086-571-89925065
- sales@amadischem.com
- Country
- China
- ProdList
- 131957
- Advantage
- 58
- Tel
- +86 18721201413
- Fax
- +86 (21) 5775-8967
- sales@biopharmaleader.com
- Country
- China
- ProdList
- 1720
- Advantage
- 58
- Tel
- 0371-0371-55051623 18137891487
- Fax
- QQ:2853979817
- 2853979817@qq.com
- Country
- China
- ProdList
- 9890
- Advantage
- 58
- Tel
- 13206083609
- 443187936@qq.com
- Country
- China
- ProdList
- 86
- Advantage
- 58
210644-62-5, SU 6668Related Search:
3-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-pyrrolidine-2,5-dione
INCB39110
X-376
Filgotinib
Decernotinib
Masitinib
Lestaurtinib
CAL-101
PLX3397 (Pexidartinib)
CO-1686
Momelotinib
790299-79-5
AZD-6244
ARRY-334543
Dovitinib
Volitinib